Through the isolation of circulating rare cells, ScreenCell is committed to contribute to the development of non-invasive approaches to the monitoring of patients with cancer and prenatal diagnosis. We are convinced that our capacity to isolate Circulating Tumor Cells and Circulating Fetal Cells will benefit of specific co-developments, particularly through combining the ScreenCell devices with existing kits to allow the use of pre-formatted and well controlled protocols as well as with cytological and molecular biology automates. Such co-developments should allow delivering improved products and services to the best benefit of patients.
Therefore, we wish develop academic collaborations, become involved in clinical trials and build co-developments with partners providing that they can positively benefit to the field of cancer and prenatal diagnosis and to the commercialization of our devices and combined technologies. This will include licensing and co-marketing.
ScreenCell is happy to have entered into the following collaborations:
- In October 2011, with Transgenomic thus enabling the combination of their sensitive Ice COLD PCR detection technology with ScreenCell CTC isolation devices.
- In May 2012, with Affymetrix for the combination of their Quantigene® View RNA ISH technology with ScreenCell CTC isolation devices thus enabling easy, accessible, sensitive, multiplex, low-cost system to enumerate and characterize CTCs and other rare cells.
- In July 2012, with Bioview combining their Automated Cell Imaging Systems for imaging of CTC’s isolated with ScreenCell’s Cyto Kit®.